title: Upregulation of serum vascular endothelial growth factor in patients with salivary gland tumor.
abstract: Neoangiogenesis is essential for tumor development, invasion, and dissemination. The most potent of the cytokines associated with angiogenesis is vascular endothelial growth factor (VEGF). The aim of the present study was to determine VEGF serum level in patients with salivary gland tumor. Using an ELISA kit, the circulating levels of VEGF in sera from 58 patients with salivary gland tumor and 30 healthy controls were assessed. Mean VEGF levels in sera of patients with salivary gland tumors (574.9 ± 414.3) were significantly higher than those in controls (263.9 ± 310.0) (P = 0.009). Within the salivary gland tumor group, mean serum VEGF concentration in malignant tumors (n = 27) was 727.3 ± 441.8 pg/mL, and that in benign tumors (n = 31) was 442.2 ± 343.3 pg/mL. Mean serum VEGF concentration was significantly higher in malignant tumors than in benign tumors (P = 0.008) and was higher in benign tumors than in controls (P = 0.03). The data in the present study clearly show that VEGF level was consistently upregulated in benign and malignant tumors in comparison to healthy controls. However, the role of VEGF as a prognostic factor in salivary gland tumor and its application in antiangiogenic therapy require further clinical research.
authors: Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Ghom Abad, Ghasrodasht Avenue, Shiraz 71956-15878, Iran.
authors: Azadeh
authors: A
authors: Andisheh Tadbir
authors: Bijan
authors: B
authors: Khademi
authors: Mahyar
authors: M
authors: Malekzadeh
authors: Maryam
authors: M
authors: Mardani
authors: Bahar
authors: B
authors: Khademi
references: Anticancer Res. 2007 Sep-Oct;27(5B):3661-6
references: 17972532
references: J Clin Oncol. 2001 Feb 15;19(4):1207-25
references: 11181687
references: Int J Oral Maxillofac Surg. 2002 Oct;31(5):495-8
references: 12418564
references: Ann Oncol. 1996 Oct;7(8):843-8
references: 8922199
references: Bioessays. 2002 Nov;24(11):1030-40
references: 12386934
references: Virchows Arch. 2000 Mar;436(3):243-8
references: 10782883
references: Oral Maxillofac Surg. 2014 Jun;18(2):187-96
references: 23456015
references: J Oncol. 2012;2012:687934
references: 22220170
references: Iran Red Crescent Med J. 2012 Jan;14(1):10-3
references: 22737547
references: Int J Oral Sci. 2010 Mar;2(1):35-44
references: 20690417
references: Pol J Pathol. 2012 Dec;63(4):255-60
references: 23359195
references: Blood. 2003 Jun 15;101(12):4878-86
references: 12586633
references: Cell. 1996 Aug 9;86(3):353-64
references: 8756718
references: J Oral Maxillofac Surg. 2007 Jan;65(1):17-21
references: 17174758
references: Oral Oncol. 2012 Mar;48(3):233-9
references: 22051188
references: Oral Oncol. 2009 Oct;45(10):920-5
references: 19502103
references: J Oral Pathol Med. 2011 Jul;40(6):456-9
references: 21138484
references: Virchows Arch. 2005 Jun;446(6):653-62
references: 15856293
references: J Exp Med. 2002 Dec 2;196(11):1497-506
references: 12461084
references: Oral Dis. 2011 Sep;17(6):590-6
references: 21624013
references: J Oral Pathol Med. 1999 Jul;28(6):259-63
references: 10426198